Form 4: Verrica Pharmaceuticals Director Acquires Stock Options

Lawrence Eichenfield, a Director at Verrica Pharmaceuticals Inc., acquired stock options for 16,000 shares of common stock.

Summary

• Lawrence Eichenfield, a Director at Verrica Pharmaceuticals Inc., was granted stock options.
• The options are for 16,000 shares of common stock.
• The exercise price for these options is $6.04 per share.
• The options are set to become exercisable starting June 5, 2026.
• The options will fully vest by the next annual stockholders' meeting, provided Eichenfield continues to serve as a director.
• Vesting occurs in 12 equal monthly installments starting July 5, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation grant to a director rather than a significant financial event or strategic shift.

Positives

• Director Eichenfield's acquisition of stock options indicates a commitment to the company's future performance.
• The stock options provide a potential upside for the director tied to the company's stock price appreciation.
• The vesting schedule aligns the director's incentives with long-term company success.

Future Outlook

The stock options are exercisable starting June 5, 2026, and will fully vest by the next annual stockholders' meeting, subject to continued service. The options expire on June 4, 2036.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the pharmaceutical industry to align executive compensation with shareholder value and incentivize long-term growth.

Stakeholder Impact

• Shareholders: The stock options represent potential future dilution if exercised, but also align director incentives with stock performance.
• Employees: This filing does not directly impact employees, but reflects standard executive compensation practices.
• Management: Director Eichenfield's compensation is directly tied to the company's stock performance through these options.

Next Steps

• Director Eichenfield will continue to serve as a director.
• The stock options will vest over time, starting July 5, 2026.
• The options will become fully exercisable by the next annual stockholders' meeting.

Key Dates

Keywords

stock options, Verrica Pharmaceuticals, Lawrence Eichenfield, director compensation, equity award, VRCA